How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment

Editorial Material Oncology

The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles

Takashi Komori

BRAIN TUMOR PATHOLOGY (2022)

Review Medicine, General & Internal

Brain Tumors in Children

Alan R. Cohen

Summary: This review focuses on the classification and prognostic significance of genetic changes in pediatric gliomas, ependymomas, and medulloblastomas, as well as their potential therapeutic targets.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial

Daniel Rodriguez et al.

Summary: This study analyzed the MRI and molecular characteristics of Diffuse Midline Gliomas (DMG) and found that regardless of H3 K27 subtype, DMG involving the thalamus had poor outcomes. Participants who underwent major debulking or total or near-total resection had longer survival, and those without leptomeningeal metastatic dissemination had better outcomes.

RADIOLOGY (2022)

Add to Collection

Review Pediatrics

Classification and Treatment of Pediatric Gliomas in the Molecular Era

Peter Hauser

Summary: The overall survival of pediatric gliomas varies depending on tumor grade, with low-grade tumors having better long-term survival and high-grade tumors having poor outcomes. Recent advancements in understanding the molecular background of pediatric gliomas are shaping the classification and treatment approaches, with molecularly targeted treatments potentially becoming a key component in managing these tumors, particularly in cases of high-grade gliomas.

CHILDREN-BASEL (2021)

Add to Collection

Review Oncology

Re-irradiation for high-grade gliomas: Has anything changed?

Sonia Garcia-Cabezas et al.

Summary: Management after recurrence or progression of high-grade gliomas remains a challenge, with re-irradiation being considered as an option. Decision-making needs to be individualized, taking into account various factors.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Genetics & Heredity

Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer

Emre Kocakavuk et al.

Summary: Ionizing radiation induces DNA damage and increases small and large deletions in tumor genomes. Effective repair of radiation-induced DNA damage is associated with worse clinical outcomes, and these genomic changes can be used to predict sensitivity to radiation therapy in recurrent cancer.

NATURE GENETICS (2021)

Add to Collection

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

Add to Collection

Article Clinical Neurology

Reirradiation practices for children with diffuse intrinsic pontine glioma

Chantel Cacciotti et al.

Summary: This study surveyed North American physicians on the practice of reirradiation for DIPG, showing that 88% of respondents consider reirradiation a treatment option, with most believing it should be done at least 6 months after initial RT. However, there was variation in total doses and fractionation, indicating the need for further clinical trials to determine optimal radiation strategies for children with progressive DIPG.

NEURO-ONCOLOGY PRACTICE (2021)

Add to Collection

Article Oncology